抽象的な
Emerging treatment in Anemia in myelofibrosis
Samer OmerA clonal hematologic malignancy called myelofibrosis causes progressive bone marrow fibrosis. Splenomegaly, constitutional symptoms, and anaemia are some of the clinical signs of MF. Anemia has a complex pathophysiology and is clinically linked to poor quality of life and worse overall survival. Allogenic stem cell transplantation is the sole curative therapy for MF, however only a small number of individuals are suitable. The efficacy of disease treatment techniques for MF-related anaemia is limited, and Janus kinase inhibitors may cause or exacerbate the condition. As a result, there is a big unmet need in the field of treating MF-related anaemia patients. This review discusses existing and novel therapies for anaemia in MF, such as momelotinib and pacritinib JAK inhibitors, luspatercept and KER-050 transforming growth factor-ligand traps, and pelabresib, a bromodomain extra-terminal domain inhibitor.